ProblemDermatology clinics lose days or weeks between a biologic decision and a real therapy start. A PubMed study found 51% of complex-dermatology prior auths were initially denied and the median delay to treatment was 12 days; Reddit patients describe waits of 5 to 6 weeks.
SolutionDermStart gives biologic coordinators one ranked worklist for new starts and renewals: missing step-therapy proof, specialty-pharmacy routing, expiring approvals, appeal deadlines, and payer-preferred drug switches for Dupixent, Skyrizi, Taltz, Stelara, and similar drugs.
Market opportunityUS dermatology already sits on a large biologics tailwind: Global Market Insights puts the US atopic dermatitis drug market at $5.5B in 2025, while dermatology software buyers already pay roughly $70 to $500 per provider monthly, which leaves room for a narrow admin wedge.